CN103764669B - 抗炎药物产品 - Google Patents

抗炎药物产品 Download PDF

Info

Publication number
CN103764669B
CN103764669B CN201280028984.3A CN201280028984A CN103764669B CN 103764669 B CN103764669 B CN 103764669B CN 201280028984 A CN201280028984 A CN 201280028984A CN 103764669 B CN103764669 B CN 103764669B
Authority
CN
China
Prior art keywords
polypeptide
residue
seq
present disclosure
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280028984.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN103764669A (zh
Inventor
安杰洛·P·孔萨尔沃
诺泽·M·梅赫塔
毛罗·佩雷蒂
杰蒙德·达利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resot Pharmaceuticals
Original Assignee
Leisuote Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leisuote Pharmaceutical Co filed Critical Leisuote Pharmaceutical Co
Publication of CN103764669A publication Critical patent/CN103764669A/zh
Application granted granted Critical
Publication of CN103764669B publication Critical patent/CN103764669B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201280028984.3A 2011-06-15 2012-06-15 抗炎药物产品 Active CN103764669B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161497270P 2011-06-15 2011-06-15
US61/497,270 2011-06-15
PCT/US2012/042699 WO2012174397A2 (en) 2011-06-15 2012-06-15 Anti-inflammatory pharmaceutical products
US13/524,381 2012-06-15
US13/524,381 US9102753B2 (en) 2011-06-15 2012-06-15 Anti-inflammatory pharmaceutical products

Publications (2)

Publication Number Publication Date
CN103764669A CN103764669A (zh) 2014-04-30
CN103764669B true CN103764669B (zh) 2017-08-15

Family

ID=47357770

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280028984.3A Active CN103764669B (zh) 2011-06-15 2012-06-15 抗炎药物产品

Country Status (12)

Country Link
US (2) US9102753B2 (https=)
EP (2) EP3533457B1 (https=)
JP (1) JP6069663B2 (https=)
CN (1) CN103764669B (https=)
AU (1) AU2012271453B2 (https=)
BR (1) BR112013032088B1 (https=)
CA (1) CA2839298C (https=)
DK (1) DK2720707T3 (https=)
ES (1) ES2712805T3 (https=)
HU (1) HUE042929T2 (https=)
PL (1) PL2720707T3 (https=)
WO (1) WO2012174397A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
US9102753B2 (en) * 2011-06-15 2015-08-11 Ugp Therapeutics, Inc. Anti-inflammatory pharmaceutical products
US9457086B2 (en) 2013-03-05 2016-10-04 Enteris Biopharma, Inc. Pharmaceuticals for oral delivery
DK3244878T3 (da) 2015-01-12 2022-10-17 Enteris Biopharma Inc Faste orale sammensætningsformer
PL4200319T3 (pl) 2020-08-21 2025-08-18 Resother Pharma A/S Preparaty peptydu n-końcowego aneksyny a1 i sposoby
CN118891273A (zh) 2022-02-23 2024-11-01 雷索特制药股份有限公司 膜联蛋白a1衍生的多肽类似物
US20250345392A1 (en) 2022-06-30 2025-11-13 Resother Pharma A/S Annexin a1 liquid pharmaceutical composition
AU2024234229A1 (en) 2023-03-13 2025-09-25 Resother Pharma A/S Annexin a1 administration regime
EP4680262A1 (en) 2023-03-13 2026-01-21 Resother Pharma A/S Annexin a1 delayed dosing

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
WO1998046722A1 (en) 1997-04-16 1998-10-22 Unigene Laboratories Inc. Direct expression of peptides into culture media
US6086018A (en) 1997-12-09 2000-07-11 Mcdonnell Douglas Corporation Interlocking assembly system for an aircraft cabin
US20090163578A1 (en) * 2004-10-01 2009-06-25 University Of Medicine And Dentistry Of New Jersey Novel modification of immunomodulatory protein
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
AU2006261909B2 (en) 2005-06-24 2011-08-11 Enteris Biopharma, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
CN101287503A (zh) * 2005-08-03 2008-10-15 Rq生物科技有限公司 用于诊断IgA和IgM介导的肾脏疾病的方法和组合物
CN101273059B (zh) 2005-08-26 2014-02-19 艾伯维有限公司 治疗活性的α-MSH类似物
US8691764B2 (en) * 2007-03-28 2014-04-08 The Research Foundation For The State University Of New York Inhibitors of NF-κB activity
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
GB0724953D0 (en) 2007-12-20 2008-01-30 Lytix Biopharma As Methods of peptide modification
EP2349321B1 (en) 2008-10-17 2020-04-22 London Health Sciences Centre Research Inc. Annexin and its use to treat inflammatory disorders
US8940697B2 (en) * 2009-10-16 2015-01-27 Duke University Compositions and methods for the treatment of myocardial ischemia/reperfusion injury with Annexin A1 short peptide
US9102753B2 (en) * 2011-06-15 2015-08-11 Ugp Therapeutics, Inc. Anti-inflammatory pharmaceutical products

Also Published As

Publication number Publication date
EP3533457B1 (en) 2021-08-11
ES2712805T3 (es) 2019-05-14
US20150315256A1 (en) 2015-11-05
US9102753B2 (en) 2015-08-11
BR112013032088B1 (pt) 2020-11-24
PL2720707T3 (pl) 2019-06-28
HUE042929T2 (hu) 2019-07-29
CA2839298C (en) 2021-05-18
CN103764669A (zh) 2014-04-30
DK2720707T3 (en) 2019-04-08
AU2012271453A1 (en) 2013-12-19
CA2839298A1 (en) 2012-12-20
EP3533457A1 (en) 2019-09-04
EP2720707B1 (en) 2018-12-19
WO2012174397A2 (en) 2012-12-20
US10072055B2 (en) 2018-09-11
WO2012174397A3 (en) 2013-02-28
JP6069663B2 (ja) 2017-02-01
US20130072446A1 (en) 2013-03-21
JP2014519526A (ja) 2014-08-14
EP2720707A4 (en) 2015-05-06
BR112013032088A2 (pt) 2016-11-22
EP2720707A2 (en) 2014-04-23
AU2012271453B2 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
CN103764669B (zh) 抗炎药物产品
EP2480567B1 (en) Thrombin c-terminal polypeptides and uses thereof for treating inflammation or coagulation disorders
PL188387B1 (pl) Białko o aktywności hamującej proteazę serynową, kompozycja farmaceutyczna, wyodrębniona sekwencja,samopowtarzający się wektor, zastosowanie białka o aktywności proteazy serynowej, sposób hamowania aktywności proteazy serynowej ex vivo i sposób wytwarzania białka
US20120189673A1 (en) Polypeptides and uses thereof
JP7621728B2 (ja) プロテアーゼ活性化受容体２のモジュレーター
JP2009526046A (ja) 新規分子
CA2588145A1 (en) Novel antimicrobial peptides
JP7734997B2 (ja) 新規な抗炎症性ペプチド及びその用途
AU758832B2 (en) Method for accelerating the rate of mucociliary clearance
CN101671390A (zh) 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
WO2014194427A1 (en) Targeted iduronate-2-sulfatase fusion proteins
KR20210147362A (ko) Nlrx1 유래의 신규한 항염증성 펩타이드 및 이의 용도
US20230295263A1 (en) Soluble thy-1 compositions and use thereof to treat or reverse fibrosis
JP2011516450A (ja) 髄膜炎に対するデフェンシンの使用
JP2006512308A (ja) 糖尿病関連及び／又は動脈低治癒性創傷の治療及び／又は予防のための、α−１−アンチキモトリプシン（ａｎｔｉｃｈｙｍｏｔｒｙｐｓｉｎ）ポリペプチドまたはそれをコードしている核酸の、α−１−アンチトリプシン（ａｎｔｉｔｒｙｐｓｉｎ）ポリペプチドまたはそれをコードしている核酸と組み合わせた使用
US20070140979A1 (en) Method for accelerating the rate of mucociliary clearance

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
CB02 Change of applicant information

Address after: Delaware

Applicant after: UGP Therapy Co.,Ltd.

Address before: Illinois State

Applicant before: UGP Therapy Co.,Ltd.

COR Change of bibliographic data
TA01 Transfer of patent application right

Effective date of registration: 20160919

Address after: Delaware

Applicant after: Endelisi Biological Pharmaceutical Co.,Ltd.

Address before: Delaware

Applicant before: UGP Therapy Co.,Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20161221

Address after: Holt, Denmark

Applicant after: Resot Pharmaceuticals

Address before: New jersey, USA

Applicant before: Endelisi Biological Pharmaceutical Co.,Ltd.

GR01 Patent grant
GR01 Patent grant